RARE
Income statement / Annual
Last year (2023), Ultragenyx Pharmaceutical Inc.'s total revenue was $434.25 M,
an increase of 19.52% from the previous year.
In 2023, Ultragenyx Pharmaceutical Inc.'s net income was -$606.64 M.
See Ultragenyx Pharmaceutical Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$434.25 M
|
$363.33 M
|
$351.41 M
|
$271.03 M
|
$103.71 M
|
$51.50 M
|
$2.61 M
|
$133,000.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$45.21 M |
$28.32 M |
$16.01 M |
$6.13 M |
$9.01 M |
$1.15 M |
$1,000.00 |
$183.20 M |
$1.38 M |
$0.00 |
| Gross Profit |
$389.04 M |
$335.01 M |
$335.40 M |
$264.90 M |
$94.71 M |
$50.35 M |
$2.61 M |
-$183.07 M |
-$1.38 M |
$0.00 |
| Gross Profit Ratio |
0.9 |
0.92 |
0.95 |
0.98 |
0.91 |
0.98 |
1 |
-1376.47 |
0 |
0 |
| Research and Development
Expenses |
$648.45 M
|
$705.79 M
|
$497.15 M
|
$412.08 M
|
$357.36 M
|
$294.00 M
|
$231.64 M
|
$183.20 M
|
$114.74 M
|
$45.97 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$127.72 M
|
$99.91 M
|
$64.94 M
|
$33.00 M
|
$10.81 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$309.80 M
|
$278.14 M
|
$219.98 M
|
$182.93 M
|
$161.52 M
|
$127.72 M
|
$99.91 M
|
$64.94 M
|
$33.00 M
|
$10.81 M
|
| Other Expenses |
$0.00 |
$9.51 M |
$241,000.00 |
$7.65 M |
$12.45 M |
$3.95 M |
$10.60 M |
$2.17 M |
-$200,000.00 |
-$3.02 M |
| Operating Expenses |
$958.25 M |
$983.93 M |
$717.14 M |
$595.02 M |
$518.88 M |
$421.72 M |
$331.55 M |
$248.14 M |
$147.74 M |
$56.78 M |
| Cost And Expenses |
$1.00 B |
$1.01 B |
$733.14 M |
$601.15 M |
$527.89 M |
$422.87 M |
$331.55 M |
$248.14 M |
$147.74 M |
$56.78 M |
| Interest Income |
$26.69 M |
$11.07 M |
$1.93 M |
$7.04 M |
$13.24 M |
$9.54 M |
$4.07 M |
$3.79 M |
$2.32 M |
$608,000.00 |
| Interest Expense |
$66.00 M |
$43.02 M |
$29.42 M |
$33.29 M |
$1.14 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$26.01 M
|
$18.20 M
|
$13.24 M
|
$12.26 M
|
$8.54 M
|
$19.54 M
|
$5.83 M
|
$3.42 M
|
$1.38 M
|
$684,000.00
|
| EBITDA |
-$516.45 M
|
-$640.51 M
|
-$410.32 M
|
-$139.81 M
|
-$389.77 M
|
-$177.56 M
|
-$312.51 M
|
-$244.58 M
|
-$146.35 M
|
-$56.09 M
|
| EBITDA Ratio |
-1.19 |
-1.76 |
-1.09 |
-1.19 |
-3.97 |
-10.52 |
-125.93 |
-1864.71 |
0 |
0 |
| Operating Income Ratio
|
-1.31
|
-1.79
|
-1.09
|
-1.22
|
-4.09
|
-7.21
|
-125.93
|
-1864.71
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$39.26 M
|
-$52.81 M
|
-$71.24 M
|
$144.76 M
|
$24.73 M
|
$174.28 M
|
$10.60 M
|
$2.17 M
|
$2.12 M
|
-$3.02 M
|
| Income Before Tax |
-$608.46 M |
-$701.73 M |
-$452.98 M |
-$185.36 M |
-$399.44 M |
-$197.10 M |
-$318.34 M |
-$245.84 M |
-$145.62 M |
-$59.80 M |
| Income Before Tax Ratio
|
-1.4
|
-1.93
|
-1.29
|
-0.68
|
-3.85
|
-3.83
|
-121.88
|
-1848.41
|
0
|
0
|
| Income Tax Expense |
-$1.83 M |
$5.70 M |
$1.04 M |
$1.21 M |
$3.28 M |
$514,000.00 |
-$16.20 M |
$35,000.00 |
-$2.32 M |
-$684,000.00 |
| Net Income |
-$606.64 M |
-$707.42 M |
-$454.03 M |
-$186.57 M |
-$402.73 M |
-$197.61 M |
-$302.14 M |
-$245.87 M |
-$145.62 M |
-$59.80 M |
| Net Income Ratio |
-1.4 |
-1.95 |
-1.29 |
-0.69 |
-3.88 |
-3.84 |
-115.67 |
-1848.68 |
0 |
0 |
| EPS |
-8.25 |
-10.12 |
-6.7 |
-3.07 |
-7.12 |
-3.97 |
-7.12 |
-6.21 |
-3.96 |
-2.08 |
| EPS Diluted |
-8.25 |
-10.12 |
-6.7 |
-3.07 |
-7.12 |
-3.97 |
-7.12 |
-6.21 |
-3.96 |
-2.08 |
| Weighted Average Shares
Out |
$73.54 M
|
$69.91 M
|
$67.80 M
|
$60.85 M
|
$56.58 M
|
$49.78 M
|
$42.45 M
|
$39.59 M
|
$36.78 M
|
$28.76 M
|
| Weighted Average Shares
Out Diluted |
$73.54 M
|
$69.91 M
|
$67.80 M
|
$60.85 M
|
$56.58 M
|
$49.78 M
|
$42.45 M
|
$39.59 M
|
$36.78 M
|
$28.76 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
